| 1 |
Soncin F, Mattot V, Lionneton F, et al. VE-statin, an endothelial repressor of smooth muscle cell migration[J]. EMBO J,2003,22(21):5700-5711.
|
| 2 |
Parker LH, Schmidt M, Jin SW, et al. The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation[J]. Nature,2004,428(6984):754-758.
|
| 3 |
Nichol D, Stuhlmann H. EGFL7: a unique angiogenic signaling factor in vascular development and disease[J]. Blood,2012,119(6):1345-1352.
|
| 4 |
Fitch MJ, Campagnolo L, Kuhnert F, et al. Egfl7, a novel epidermal growth factor-domain gene expressed in endothelial cells[J]. Dev Dyn,2004,230(2):316-324.
|
| 5 |
Fan C, Yang LY, Wu F, et al. The expression of Egfl7 in human normal tissues and epithelial tumors[J]. Int J Biol Markers,2013,28(1):71-83.
|
| 6 |
Sun Y, Bai Y, Zhang F, et al. miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7[J]. Biochem Biophys Res Commun,2010,391(3):1483-1489.
|
| 7 |
Sieg DJ, Hauck CR, Ilic D, et al. FAK integrates growth-factor and integrin signals to promote cell migration[J]. Nat Cell Biol,2000,2(5):249-256.
|
| 8 |
Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives[J]. Cancer Lett,2012,320(2):130-137.
|
| 9 |
桑娜，李景和，王宽松. EGFL7与肿瘤研究新进展[J]. 现代生物医学进展,2009,9(23):4556-4559.
|
| 10 |
Durrans A, Stuhlmann H. A role for Egfl7 during endothelial organization in the embryoid body model system[J]. J Angiogenes Res,2010,2:4.
|
| 11 |
Nikolic I, Stankovic ND, Bicker F, et al. EGFL7 ligates alphavbeta3 integrin to enhance vessel formation[J]. Blood,2013,121(15):3041-3050.
|
| 12 |
Schmidt M, Paes K, De Maziere A, et al. EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution[J]. Development,2007,134(16):2913-2923.
|
| 13 |
Campagnolo L, Leahy A, Chitnis S, et al. EGFL7 is a chemoattractant for endothelial cells and is up-regulated in angiogenesis and arterial injury[J]. Am J Pathol,2005,167(1):275-284.
|
| 14 |
Schmidt M, De Maziere A, Smyczek T, et al. The role of Egfl7 in vascular morphogenesis[J]. Novartis Found Symp,2007,283:18-28, 28-36, 238-241.
|
| 15 |
Wu F, Yang LY, Li YF, et al. Novel role for epidermal growth factor-like domain 7 in metastasis of human hepatocellular carcinoma[J]. Hepatology,2009,50(6):1839-1850.
|
| 16 |
Campagnolo L, Telesca C, Massimiani M, et al. Different expression of VEGF and EGFL7 in human hepatocellular carcinoma[J]. Dig Liver Dis,2016,48(1):76-80.
|
| 17 |
Huang C, Yuan X, Wan Y, et al. VE-statin/Egfl7 expression in malignant glioma and its relevant molecular network[J]. Int J Clin Exp Pathol,2014,7(3):1022-1031.
|
| 18 |
Wang FY, Kang CS, Wang-Gou SY, et al. EGFL7 is an intercellular EGFR signal messenger that plays an oncogenic role in glioma[J]. Cancer Lett,2017,384:9-18.
|
| 19 |
Zhou L, Li J, Zhao YP, et al. Prognostic significance of epidermal growth factor-like domain 7 in pancreatic cancer[J]. Hepatobiliary Pancreat Dis Int,2014,13(5):523-528.
|
| 20 |
Shen X, Han Y, Xue X, et al. Epidermal growth factor-like domain 7 promotes cell invasion and angiogenesis in pancreatic carcinoma[J]. Biomed Pharmacother,2016,77:167-175.
|
| 21 |
Oh J, Park SH, Lee TS, et al. High expression of epidermal growth factor-like domain 7 is correlated with poor differentiation and poor prognosis in patients with epithelial ovarian cancer[J]. J Gynecol Oncol,2014,25(4):334-341.
|
| 22 |
Li JJ, Yang XM, Wang SH, et al. Prognostic role of epidermal growth factor-like domain 7 protein expression in laryngeal squamous cell carcinoma[J]. J Laryngol Otol,2011,125(11):1152-1157.
|
| 23 |
Deng QJ, Xie LQ, Li H. Overexpressed MALAT1 promotes invasion and metastasis of gastric cancer cells via increasing EGFL7 expression[J]. Life Sci,2016,157:38-44.
|
| 24 |
Philippin-Lauridant G, Baranzelli MC, Samson C, et al. Expression of Egfl7 correlates with low-grade invasive lesions in human breast cancer[J]. Int J Oncol,2013,42(4):1367-1375.
|
| 25 |
Garcia-Carbonero R, van Cutsem E, Rivera F, et al. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer[J]. Oncologist,2017.
|
| 26 |
Perlikos F, Harrington KJ, Syrigos KN. Key molecular mechanisms in lung cancer invasion and metastasis: a comprehensive review[J]. Crit Rev Oncol Hematol,2013,87(1):1-11.
|
| 27 |
Luo BH, Xiong F, Wang JP, et al. Epidermal growth factor-like domain-containing protein 7 (EGFL7) enhances EGF receptor-AKT signaling, epithelial-mesenchymal transition, and metastasis of gastric cancer cells[J]. PLoS One,2014,9(6):e99922.
|
| 28 |
Pinte S, Soncin F. Egfl7 promotes tumor escape from immunity[J]. Oncoimmunology,2012,1(3):375-376.
|
| 29 |
Takao Y. 7. Inspection of Hepatocellular Carcinoma 5: Angiography[J]. Nihon Hoshasen Gijutsu Gakkai Zasshi,2016,72(7):627-635.
|
| 30 |
Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy[J]. Science,2005,307(5706):58-62.
|
| 31 |
Badiwala MV, Tumiati LC, Joseph JM, et al. Epidermal growth factor-like domain 7 suppresses intercellular adhesion molecule 1 expression in response to hypoxia/reoxygenation injury in human coronary artery endothelial cells[J]. Circulation,2010,122(11 Suppl):S156-S161.
|
| 32 |
Liu YS, Huang ZW, Qin AQ, et al. The expression of epidermal growth factor-like domain 7 regulated by oxygen tension via hypoxia inducible factor (HIF)-1alpha activity[J]. Postgrad Med,2015,127(2):144-149.
|
| 33 |
Nichol D, Stuhlmann H. EGFL7: a unique angiogenic signaling factor in vascular development and disease[J]. Blood,2012,119(6):1345-1352.
|
| 34 |
Cui H, He J, Chen H, et al. Erythropoietin attenuates hyperoxia-induced lung injury by upregulating epidermal growth factor-like domain 7 in newborn rats[J]. Biomed Rep,2017,6(1):32-38.
|